|Articles|September 9, 2022
- Pharmaceutical Executive-09-01-2022
- Volume 42
- Issue 9
Pharmaceutical Executive, September 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
ESG: Applying Lessons From Consumer Marketover 3 years ago
21st Annual Industry Audit: Pharma Performance Checkover 3 years ago
The Manufacturing Edge on Path to Marketover 3 years ago
How Good is a Good Product Launch?over 3 years ago
More Than a Name: Vyvgartover 3 years ago
Fighting Vision Loss: Vabysmoover 3 years ago
A Sleeping Giant?: Quviviqover 3 years ago
Next-level Efficacy: MounjaroNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Your Phase III Clinical Protocol Is Your Initial Product Launch
2
Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
3
AstraZeneca Enters $4.7 Billion Collaboration Agreement with CSPC Pharmaceuticals
4
Taking Advantage of ‘Hidden Gem’ Talent Hubs
5
